IL-15-based fusions to IL-7 and IL-21
The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
1. A soluble fusion protein complex comprising:
a first fusion protein comprising interleukin-7 (IL-7) (SEQ ID NO:10) and interleukin-15 receptor alpha sushi-binding domain/Fc (IL-15RαSu/Fc) (SEQ ID NO:8); and
a second fusion protein comprising interleukin-21 (IL-21) (SEQ ID NO:6) and an IL-15 variant comprising an N72D mutation (IL-15N72D) (SEQ ID NO:12) or human wild-type IL-15,
wherein the first and second fusion proteins are non-covalently linked to form the soluble fusion protein complex.
2. The soluble fusion protein complex of claim 1 , wherein the IL-7 is attached to the N-terminus of the IL-15RαSu/Fc.
3. The soluble fusion protein complex of claim 1 , wherein the IL-7 is attached to the C-terminus of the IL-15RαSu/Fc.
4. The soluble fusion protein complex of claim 2 , wherein the IL-21 is attached to the N-terminus of the IL-15N72D or the human wild-type IL15.
5. The soluble fusion protein complex of claim 2 , wherein the IL-21 is attached to the C-terminus of the IL-15N72D or the human wild-type IL-15.
6. The soluble fusion protein complex of claim 3 , wherein the IL-21 is attached to the N-terminus of the IL-15N72D or the human wild-type IL-15.
7. The soluble fusion protein complex of claim 3 , wherein the IL-21 is attached to the C-terminus of the IL-15N72D or the human wild-type IL-15.
8. The soluble fusion protein complex of claim 1 , wherein the soluble fusion protein complex is covalently linked to a second soluble fusion protein complex by a disulfide bond linking the Fc domain of the first soluble fusion protein complex to an Fc domain of the second soluble fusion protein complex, wherein the second soluble fusion protein complex is identical to the first soluble fusion protein complex.